The need for new antibiotics

House of Lords Select Committee on Science and Technology. Resistance to Antibiotics and Other Antimicrobial Agents, Session 1997–8. TSO 1998. UK Standing Medical Advisory Committee (SMAC), 1998 European Commission BD. Opinion of the Scientific Steering Committee on Antimicrobial Resistance, Brussels 2003. Anonymous, 2001 Interagency Task Force on Antibiotic Resistance Livermore, 2003, Bacterial resistance. origins, epidemiology, and impact, Clin Infect Dis, 36, S11, 10.1086/344654 Gruneberg, 2002, Global surveillance through PROTEKT. the first year, J Chemother, 14, 9, 10.1080/1120009X.2002.11782347 Aarestrup, 2001, Effect of abolishment of the use of antimicrobial agents for growth promotion on occurrence of antimicrobial resistance in fecal enterococci from food animals in Denmark, Antimicrob Agents Chemother, 45, 2054, 10.1128/AAC.45.7.2054-2059.2001 Mendelson, 2003, Staphylococcus aureus carrier state among elderly residents of a long-term care facility, J Am Med Dir Assoc, 4, 125, 10.1016/S1525-8610(04)70320-5 Wiener, 1999, Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes, JAMA, 281, 517, 10.1001/jama.281.6.517 Soares, 1993, Evidence for the introduction of a multiresistant clone of serotype 6B Streptococcus pneumoniae from Spain to Iceland in the late 1980s, J Infect Dis, 168, 158, 10.1093/infdis/168.1.158 Gillespie, 2001, Antibiotic resistance in the absence of selective pressure, Int J Antimicrob Agents, 17, 171, 10.1016/S0924-8579(00)00340-X Lenski, 1997, The cost of antibiotic resistance – from the perspective of a bacterium, Ciba Found Symp, 207, 131 Livermore, 2003, In-vitro activity of piperacillin/tazobactam and other broad-spectrum antibiotics against bacteria from hospitalised patients in the British Isles, Int J Antimicrob Agents, 22, 14, 10.1016/S0924-8579(03)00108-0 Bergogne-Berezin, 1996, Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features, Clin Microbiol Rev, 9, 148, 10.1128/CMR.9.2.148 Nordmann, 2002, Emerging carbapenemases in Gram-negative aerobes, Clin Microbiol Infect, 8, 321, 10.1046/j.1469-0691.2002.00401.x Jones, 2003, Contemporary in vitro spectrum of activity summary for antimicrobial agents tested against 18569 strains non-fermentative Gram-negative bacilli isolated in the SENTRY Antimicrobial Surveillance Program (1997–2001), Int J Antimicrob Agents, 22, 551, 10.1016/S0924-8579(03)00245-0 Coelho, 2004, Multiresistant Acinetobacter in the UK. how big a threat?, J Hosp Infect, 10.1016/j.jhin.2003.12.019 Lambert, 1988, Transferable amikacin resistance in Acinetobacter spp. due to a new type of 3′-aminoglycoside phosphotransferase, Antimicrob Agents Chemother, 32, 15, 10.1128/AAC.32.1.15 Levin, 1999, Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, Clin Infect Dis, 28, 1008, 10.1086/514732 Livermore, 2003, Threat from the pink corner, Ann Med, 35, 226, 10.1080/07853890310001609 Karlowsky, 2003, Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998–2001, Antimicrob Agents Chemother, 47, 1681, 10.1128/AAC.47.5.1681-1688.2003 Livermore, 2002, Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa, our worst nightmare?, Clin Infect Dis, 34, 634, 10.1086/338782 Oliver, 2000, High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection, Science, 288, 1251, 10.1126/science.288.5469.1251 Lee, 2002, bla(VIM-2) cassette-containing novel integrons in metallo-β-lactamase-producing Pseudomonas aeruginosa and Pseudomonas putida isolates disseminated in a Korean hospital, Antimicrob Agents Chemother, 46, 1053, 10.1128/AAC.46.4.1053-1058.2002 Gales, 2003, Dissemination in distinct Brazilian regions of an epidemic carbapenem-resistant Pseudomonas aeruginosa producing SPM metallo-β-lactamase, J Antimicrob Chemother, 52, 699, 10.1093/jac/dkg416 Livermore, 2002, Trends in fluoroquinolone (ciprofloxacin) resistance among Enterobacteriaceae from bactermias in England and Wales 1990–1999, Emerg Infect Dis, 8, 473, 10.3201/eid0805.010204 Karlowsky, 2003, Trends in antimicrobial susceptibilities among Enterobacteriaceae isolated from hospitalized patients in the United States from 1998 to 2001, Antimicrob Agents Chemother, 47, 1672, 10.1128/AAC.47.5.1672-1680.2003 Chow, 1991, Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy, Ann Intern Med, 115, 585, 10.7326/0003-4819-115-8-585 Livermore, 2004, Should third-generation cephalosporins be avoided against AmpC-inducible Enterobacteriaceae?, Clin Microbiol Infect, 10, 84, 10.1111/j.1469-0691.2004.00831.x Yuan, 1998, Epidemiological typing of klebsiellae with extended-spectrum β-lactamases from European intensive care units, J Antimicrob Chemother, 41, 527, 10.1093/jac/41.5.527 Arlet, 1994, Molecular epidemiology of Klebsiella pneumoniae strains that produce SHV-4 β-lactamase and which were isolated in 14 French hospitals, J Clin Microbiol, 32, 2553, 10.1128/JCM.32.10.2553-2558.1994 De Gheldre, 2001, National epidemiologic surveys of Enterobacter aerogenes in Belgian Hospitals from 199 to 1998, J Clin Microbiol, 39, 889, 10.1128/JCM.39.3.889-896.2001 Winokur, 2001, Variations in the prevalence of strains expressing an extended-spectrum β-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region, Clin Infect Dis, 32, S94, 10.1086/320182 Radice, 2002, Early dissemination of CTX-M-derived enzymes in South America, Antimicrob Agents Chemother, 46, 602, 10.1128/AAC.46.2.602-604.2002 Bonnet, 2004, Growing group of extended-spectrum β-lactamases: the CTX-M enzymes, Antimicrob Agents Chemother, 48, 1, 10.1128/AAC.48.1.1-14.2004 Cooper, 2003, Systematic review of isolation policies in the hospital management of methicillin-resistant Staphylococcus aureus: a review of the literature with epidemiological and economic modelling, Health Technol Assess, 7, 1, 10.3310/hta7390 Johnson, 2001, Dominance of EMRSA-15 and -16 among MRSA causing nosocomial bacteraemia in the UK. Analysis of isolates from the European Antimicrobial Resistance Surveillance System (EARSS), J Antimicrob Chemother, 48, 144, 10.1093/jac/48.1.143 Wunderink, 2003, Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia, Chest, 124, 1789, 10.1016/S0012-3692(15)33412-7 Johnson, 2002, In vitro activity of cephalosporin RWJ-54428 (MC-02479) against multidrug-resistant gram-positive cocci, Antimicrob Agents Chemother, 46, 321, 10.1128/AAC.46.2.321-326.2002 Entenza, 2002, BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis, Antimicrob Agents Chemother, 46, 171, 10.1128/AAC.46.1.171-177.2002 Zumia, 2001, Multidrug-resistant tuberculosis – can the tide be turned?, Lancet Infect Dis, 1, 199, 10.1016/S1473-3099(01)00096-2 Woodford N, Ward E, Kaufmann CE. Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum β-lactamases (ESBLs) in the UK. J Antimicrob Chemother; in press. Fenton, 2003, Ciprofloxacin resistance in Neisseria gonorrhoeae in England and Wales in 2002, Lancet, 361, 1867, 10.1016/S0140-6736(03)13489-7 Corkill, 2003, Molecular epidemiology of endemic ciprofloxacin-resistant Neisseria gonorrhoeae in Liverpool, Int J STD AIDS, 14, 379, 10.1258/095646203765371259